Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates

Transfusion
Andreas BertingThomas R Kreil

Abstract

To enhance the viral safety margins, nanofiltration has been widely integrated into the manufacturing process of plasma-derived medicinal products. Removal of smaller agents such as parvovirus B19 (B19V) by filtration, however, is typically less efficient. Because recent investigations have demonstrated that B19V may be more heat sensitive than animal parvoviruses, the potential B19V inactivation by a proprietary vapor heating procedure (STIM-4) as incorporated into the manufacturing processes of several nanofiltered coagulation factor concentrates was investigated. An infectivity assay based on quantitative reverse transcription-polymerase chain reaction (TaqMan, Applied Biosystems) detection of B19V mRNA after inoculation of a permissive cell line (UT7 Epo S1 cells) was used to investigate the virus inactivation capacity of the STIM-4 vapor heat treatment as used during the manufacture of nanofiltered second-generation Factor VIII inhibitor-bypassing activity (FEIBA), F IX complex, and FVII products. In contrast to animal parvoviruses, both B19V genotypes investigated, that is, 1 and 2, were shown to be surprisingly effectively inactivated by the STIM-4 vapor heat treatment process, with mean log reduction factors of 3.5 to 4...Continue Reading

References

Jan 11, 1975·Lancet·Y E CossartD Widdows
Aug 1, 1987·Journal of Virology·K OzawaN Young
Jul 16, 1999·Journal of Clinical Microbiology·Q T NguyenA Garbarg-Chenon
Jul 26, 2000·Current Opinion in Rheumatology·T L Moore
Aug 31, 2000·Biologicals : Journal of the International Association of Biological Standardization·P L Roberts, H Hart
Aug 21, 2002·Journal of Virology·Annabelle ServantAntoine Garbarg-Chenon
Oct 19, 2002·Transfusion·Johannes BlümelJohannes Löwer
Nov 8, 2002·Transfusion·Johannes BlümelAnna Maria Eis-Hübinger
Feb 1, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·T Burnouf, M Radosevich
Apr 3, 2003·Vox Sanguinis·M YunokiK Ikuta
Feb 6, 2004·The New England Journal of Medicine·Neal S Young, Kevin E Brown
May 18, 2004·Vox Sanguinis·T YokoyamaT Tomono
Jul 1, 2004·Transfusion·Nicola BoschettiJohannes Blümel
Oct 7, 2004·Thrombosis and Haemostasis·Beate SchneiderAnna Maria Eis-Hübinger
Aug 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Tobias AllanderBjörn Andersson
Oct 29, 2005·Journal of Virology·Johannes BlümelJohannes Löwer
Dec 1, 2005·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·S PankuweitB Maisch
Feb 4, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Susan Wong, Kevin E Brown
Feb 24, 2006·Emerging Infectious Diseases·Jacqueline F FryerSally A Baylis
Apr 6, 2007·Journal of Virology·Anna EkmanMaria Söderlund-Venermo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.